Neuros Medical Receives FDA Breakthrough Device Designation for its Novel Altius® High-Frequency Nerve Block System
On June 29, 2021, the US Food and Drug Administration (FDA) granted Neuros Medical, Inc. Breakthrough Device Designation for the use of their unique Altius High-Frequency Nerve Block device in the management of chronic intractable pain of the lower limb in adult amputees.
By the fall of 2021, Neuros expects completion of enrollment in its pivotal QUEST (High-FreQUEncy Nerve Block for PoST-Amputation Pain) study. QUEST is a 180-subject, randomized, double-blinded, active sham-controlled clinical trial that is being conducted under an investigat...
